17results about "Lipocortins" patented technology

A drug for treating osteoporosis. Provided is the use of annexin A5 in the preparation of a composition or preparation having one or more uses selected from the group consisting of: (i) preventing and / or treating osteoporosis; (ii) inhibiting osteoclast activity; and (iii) reducing bone loss. The annexin A5 can prevent and / or treat osteoporosis by means of inhibiting osteoclast activity and preventing bone loss.

The invention relates to novel methods, uses and compositions of a molecule consisting of monomeric Annexin A5 protein, for the prophylaxis or the treatment of macular oedema and / or one or more diseases, disorders or conditions associated with, and / or caused by, macular oedema. In a preferred embodiment, the Annexin A5 is administered systemically, such as intravenously.

The present disclosure relates to polypeptides and polypeptide analogs derived from Annexin A1, and compositions comprising said polypeptides or polypeptide analogs for treating inflammatory and ischemic conditions.

The present invention provides synthetic polypeptides comprising an annexin V protein, or a functional portion or fragment or variant thereof, conjugated to a tumor antigen, or a functional portion or fragment or variant thereof. The invention further provides methods for making said synthetic polypeptides and their use in the treatment of proliferative diseases such as cancer and tumors originating therefrom.

Combinations of an apyrase and an annexin, including fusion proteins thereof, are synergistic antithrombotics that do not induce unwanted bleeding.

The present invention provides a composition having moisturizing, repairing, firming, and anti-wrinkle effects, and its use. The present invention belongs to the field of pharmaceuticals or personal care products and provides a pharmaceutical or personal care composition having moisturizing, repairing, firming, and anti-wrinkle effects, and its use. Specifically, the present invention provides an application of an annexin, which has been verified to have moisturizing, repairing, firming, and anti-wrinkle effects through cell and human efficacy tests. Human efficacy test results show that pharmaceutical or personal care compositions containing the above-mentioned protein have significant effects in moisturizing, repairing, firming, and anti-wrinkle.

A composition for treating inflammatory, neoplastic and obstructive lung diseases featuring a CC16-derived analog is described herein. The analog may include N-terminal acetylation and C -terminal amidation, enhancing stability. Adopting a helical conformation, the CC16-derived analog maintains activity akin to full-length CC16 protein. Effective for diverse lung diseases, the composition allows aerosolization, subcutaneous injection, and pulmonary delivery, with administration options including nasal inhalation, subcutaneous, or oral routes. A method for treating these diseases involves administering the CC16-derived analog to a subject in need. This innovation offers a versatile, efficacious solution for respiratory conditions, providing tailored treatment approaches.

To provide processes for the manufacture of protein comprising the sequence of Annexin A5 (AnxA5).SOLUTION: Provided is a process for recovery and / or purification of a recombinantly expressed intracellular protein comprising a sequence of Annexin A5 (AnxA5) from an endotoxin-producing host cell with a cell wall. The process comprises releasing the intracellular protein from the host cell, and is characterized in that the step of releasing the intracellular AnxA5 protein is conducted in presence of a homogenization buffer comprising non-ionic detergent. Therein, the process preferably does not include any centrifugation steps for the recovery and / or purification of the AnxA5 protein after the release thereof from the host cell, and / or the AnxA5 protein remains in solution throughout the process, except when temporarily bound to any chromatographic resins.SELECTED DRAWING: Figure 2

The present invention provides a labelled cell stress marker for use in identifying or predicting angiogenesis in a subject. Also provided is a method of identifying or predicting angiogenesis in a subject, the subject having been administered a labelled cell stress marker. The method comprises the steps of (a) generating an image from the subject using a first imaging device and (b) identifying labelled cell stress marker positive cell(s) in the image. Angiogenesis is identified or predicted if labelled cell stress marker positive cell(s) are identified in the image.

The present invention relates to pharmaceutical formulations comprising a therapeutically effective amount of an Annexin A1 (AnxA1) N-terminal-peptide having improved solubility and / or stability, while retaining agonistic activity at one or more of the formyl peptide receptors, including FPR1, FPR2 and FPR3.

The present invention relates to pharmaceutical formulations comprising a therapeutically effective amount of an Annexin A1 (AnxA1) N-terminal-peptide having improved solubility and / or stability, while retaining agonistic activity at one or more of the formyl peptide receptors, including FPR1, FPR2 and FPR3.

The combination of apyrase and annexin, including the fusion protein, is a synergistic antithrombotic agent that does not induce unwanted bleeding.

Disclosed are methods for selecting or identifying fusion-competent gametes. The methods can include providing a sample including gametes obtained from a subject; and contacting the sample with a reagent capable of binding Myomerger expressed on the surface of the gametes. The methods can also include isolating gametes bound by the reagent capable of binding Myomerger from gametes not bound by the reagent capable of binding Myomerger. Also disclosed are methods for contraception that include administering a reagent capable of binding Myomerger expressed on the surface of gametes to a subject. Also disclosed are compositions that include a reagent capable of binding Myomerger and a reagent capable of binding phosphatidylserine, as are kits that include the disclosed compositions.

The targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein.

Composition and methods are provided for the treatment of a mammalian subject for axonopathies by increasing activity of axon regeneration-associated gene (RAG) as identified herein, which include without limitation ANXA2, TPA, GSN, VIM, MPP1, ILK, ECM1, CALM1, AND ACAA2. These genes are shown to significantly promote axon regeneration, dramatically protects retinal ganglion cells and optic nerves, and preserve visual function in a clinically relevant model of glaucoma. A therapeutic entity may comprise, for example, a RAG protein, a gene therapy vector comprising a RAG coding sequence, a small molecule that enhances RAG activity, and the like.

The present invention relates to a novel method, use, and composition of a molecule consisting of monomeric annexin A5 protein for the prevention or treatment of macular edema and one or more diseases, disorders, or conditions associated with and / or caused by macular edema. In a preferred embodiment, annexin A5 is administered systemically, for example, by intravenous administration.

The present disclosure relates to polypeptides and polypeptide analogues derived from Annexin A1 as well as compositions comprising said polypeptides or polypeptide analogues for treatment of inflammatory and ischemic conditions.